Preferred Label : ataluren;
MeSH note : overrides nonsense stop translation signals to yield full-length proteins; may prove
useful in treating cystic fibrosis and Duchenne muscular dystrophy;
CISMeF synonym : PTC 124;
MeSH hyponym : PTC124; PTC-124;
Is substance : O;
UNII : K16AME9I3V;
Origin ID : C515878;
UMLS CUI : C2930764;
ATC code(s)
- CISMeF manual mappings
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3554883/fr/translarna-ataluren-dystrophie-musculaire-de-duchenne
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
ataluren
child
evaluation of the transparency committee
ataluren
muscular dystrophy, duchenne
---
https://www.has-sante.fr/jcms/p_3118134/fr/translarna
2019
false
false
false
France
ataluren
treatment outcome
insurance, health, reimbursement
administration, oral
ataluren
muscular dystrophy, duchenne
child
evaluation of the transparency committee
oxadiazoles
---
https://www.has-sante.fr/portail/jcms/c_2779824/fr/translarna
https://www.has-sante.fr/portail/jcms/c_2779824/fr/translarna-ataluren-arn-interferant
2017
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
guidelines for drug use
ataluren
ataluren
orphan drug production
muscular dystrophy, duchenne
child
adult
adolescent
rna interference
ataluren
dystrophin
mutation, nonsense
oxadiazoles
oxadiazoles
codon, nonsense
---
http://www.has-sante.fr/portail/jcms/c_2009663/fr/translarna
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
guidelines for drug use
ataluren
ataluren
rare diseases
orphan drug production
muscular dystrophy, duchenne
child
adult
adolescent
rna interference
ataluren
oxadiazoles
oxadiazoles
---
https://www.ema.europa.eu/medicines/human/EPAR/Translarna
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
orphan drug production
ataluren
ataluren
muscular dystrophy, duchenne
muscular dystrophy, duchenne
mutation, nonsense
codon, nonsense
rare diseases
administration, oral
dystrophin
DMD protein, human
risk assessment
product surveillance, postmarketing
drug monitoring
child
adolescent
adult
genetic testing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ataluren
oxadiazoles
oxadiazoles
---
